

Annual Report and Audited Financial Statements for the year ended 30 June 2023



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

Contents	Page
General Information	3
Investment Manager's Report	4
Directors' Report	6
Independent Auditor's Report	8
Custodian's Report	11
Supplementary Information	12
Portfolio Statement	13
Statement of Financial Position	14
Statement of Comprehensive Income	15
Statement of Cash Flows	16
Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares	17
Notes to the Financial Statements	18



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **General Information**

# **Address and Registered Office**

PO Box 255

Trafalgar Court, Les Banques St Peter Port, Guernsey

GY13QL

Channel Islands

#### **Investment Manager**

Momentum Global Investment Management Limited

The Rex Building 62 Queen Street

London

EC4R 1EB

**United Kingdom** 

#### **Distribution Partner**

Vickers & Peters Financial Planning 2nd Floor, 1 Melrose Boulevard

Melrose Arch

2196

South Africa

# Manager

Momentum Wealth International Limited

La Plaiderie House

La Plaiderie

St Peter Port, Guernsey

**GY1 1WF** 

Channel Islands

#### Custodian

Northern Trust (Guernsey) Limited

PO Box 71

**Trafalgar Court** 

Les Banques

St Peter Port, Guernsey

GY1 3DA

**Channel Islands** 

# **Directors of the Incorporated Cell**

**Robert Alastair Rhodes** 

**Roxanne Power** 

Marie Curutchet

Ferdinand van Heerden

Ray Mhere - appointed 25 May 2023

Kapil Joshi - resigned 25 May 2023

# **Administrator, Registrar & Secretary**

Northern Trust International Fund Administration

Services (Guernsey) Limited

PO Box 255

**Trafalgar Court** 

Les Banques

St Peter Port, Guernsey

GY13QL

Channel Islands

# **Legal Advisor**

Carey Olsen

**Carey House** 

Les Banques

St Peter Port, Guernsey

GY1 4BZ

**Channel Islands** 

# **Independent Auditor**

Ernst & Young LLP

PO Box 9

**Royal Chambers** 

St Julian's Avenue

St Peter Port, Guernsey

GY1 4AF

Channel Islands

#### **Sub-Investment Manager**

Ampersand Asset Management (Pty) Limited

2nd Floor, 1 Melrose Boulevard

Melrose Arch

2196

South Africa




# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Investment Manager's Report**

At the beginning of the period, as at 1 July 2022, the Russian invasion of Ukraine and soaring global inflation culminated in one of the poorest 6-month performances in the last century. Both international bond and equity markets were down significantly as at 1 July 2022.

Subsequently, over the last 12-month period ending 30 June 2023, international equity markets have recovered substantially (in USD) whilst bond and property markets continued to take strain on the back of rising interest rates.



30/06/2022 - 30/06/2023 Data from FE fundinfo2023

### Performance Data Source: Profile Data 30 June 2023 (USD)


Performance KEY:

MSCI ACWI = Global Equity

FTSE EPRA Nareit = Global Property

FTSE World Government Bond = Global Bonds

Over the last 12 months the single most influential driver of both asset class returns and short-term volatility has been the US Federal reserve interest rate policy. Despite inflation coming down significantly, several other factors, such as a continued strong labour market, have made it difficult to anticipate the top of the hiking cycle.




Data Source: Trading Economics Sep 2023



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Investment Manager's Report (continued)**

#### **Fund Performance:**



01/07/2022 - 30/06/2023 Data from FE fundinfo2023

#### Performance Data Source: Profile Data 30 June 2023 (USD)

The VPFP International Cautious Fund lagged its benchmark by 0.09% on a net of fees and costs basis. The performance relative to benchmark is in line with what is expected, given that the portfolio is managed to replicate its benchmark on a gross of fees basis. On a peer relative basis, the portfolio delivered a return in excess of its respective international category average.

### **Fund Positioning:**

The portfolio follows a strategic asset allocation approach whereby the benchmark represents our view of the optimal static/strategic asset allocation for the fund to achieve its performance objective into the future. The portfolio does not aim to outperform its benchmark but rather to replicate the benchmark as closely as possible. The reason for following this approach is a result of our belief that tactical asset allocation and active management tend to detract rather than enhance benchmark relative performance.

In order to further reduce benchmark relative tracking error (with the exception of global government bonds) the portfolio is constructed using index tracking mutual funds and ETFs. In this context we are happy with the benchmark relative performance of the portfolio after fees, taking into account that our benchmark returns do not account for any fees or costs.

We firmly believe that following the approach described will in time lead to better absolute return outcomes.



#### Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Directors' Report**

The Directors present their annual report together with the audited financial statements of VPFP International Cautious Fund IC Limited (the "Incorporated Cell" or the "Cell") for the year ended 30 June 2023.

### **Principal activities**

The Cell with company number 50897 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company"). The activities and objectives of the Cell can be found in note 1 on page 18.

#### **Going concern**

The Directors have made an assessment of going concern including consideration of geo-political issues on the Cell. Refer to note 2 for the detailed disclosure.

#### **Directors**

The Directors of the Cell during the year and at the date of this report are set out on page 3.

#### **Directors' interests**

None of the Directors who held office during the year and at the date of this report had any disclosable interests in the shares of the Incorporated Cell.

#### Directors' responsibilities

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Incorporated Cell and of the profit or loss of the Cell for that period. In preparing these financial statements the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Incorporated Cell will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Incorporated Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020. They are also responsible for safeguarding the assets of the Incorporated Cell and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as each Director is aware, there is no relevant audit information of which the Incorporated Cell's auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Incorporated Cell's auditor is aware of that information.

The Board of Directors confirms that, throughout the period covered by the financial statements, the Cell complied with the Code of Corporate Governance issued by the Guernsey Financial Services Commission, to the extent it was applicable based upon its legal and operating structure and its nature, scale and complexity.

The annual report together with the audited financial statements of the Incorporated Cell are published on the Manager's website. The Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website. The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

# **Directors' Report (continued)**

# **Independent auditors**

Ernst & Young LLP have indicated their willingness to continue in office. The reappointment of Ernst & Young LLP will be proposed within the next written resolution to deal with annual business.

**Marie Curutchet** 

Director

30 November 2023

**Robert Rhodes** 

Director



#### Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### Independent Auditor's Report to the Members of VPFP International Cautious Fund IC Limited

#### **Opinion**

We have audited the financial statements of VPFP International Cautious Fund IC Limited (the "Incorporated Cell") for the year ended 30 June 2023 which comprise the Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares, and the related notes 1 to 16, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- give a true and fair view of the state of the Incorporated Cell's affairs as at 30 June 2023 and of its profit for the year then ended;
- have been properly prepared in accordance with International Financial Reporting Standards; and
- have been properly prepared in accordance with the requirements of The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Incorporated Cell in accordance with the ethical requirements that are relevant to our audit of the financial statements, including the UK FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Incorporated Cell's ability to continue as a going concern for the period to 31 December 2024.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Incorporated Cell's ability to continue as a going concern.

#### Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

### Independent Auditor's Report to the Members of VPFP International Cautious Fund IC Limited (continued)

#### Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which The Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Incorporated Cell; or
- the financial statements are not in agreement with the Incorporated Cell's accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

#### **Responsibilities of directors**

As explained more fully in the directors' responsibilities statement set out on page 6, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Incorporated Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Incorporated Cell or to cease operations, or have no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

#### Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

- We obtained an understanding of the legal and regulatory frameworks that are applicable to the Incorporated Cell and determined that the most significant are those that relate to the reporting framework (International Financial Reporting Standards, The Companies (Guernsey) Law, 2008 and the Protection of Investors (Bailiwick of Guernsey) Law, 2020);
- We understood how the Incorporated Cell is complying with those frameworks by making enquiries of management and those responsible for compliance matters and corroborated this by reviewing minutes of meetings of the Board of Directors and correspondence between the Incorporated Cell and the Guernsey Financial Services Commission. We gained an understanding of the Board's approach to governance, demonstrated by its review of compliance reports, the investment manager's reports and internal control processes;
- We assessed the susceptibility of the Incorporated Cell's financial statements to material misstatement, including how
  fraud might occur by considering the risk of management override and by identifying the valuation of investments
  (specifically manual price overrides) and the recognition of dividend income at year-end (cut-off) as fraud risks. We
  considered the controls the Incorporated Cell has established to address the risk identified by the directors or that
  otherwise seek to prevent, detect or deter fraud and how management and those charged with governance monitor
  those controls. We also considered the existence of any stakeholder influences which may cause management to seek
  to manipulate the financial performance and did not note any;



#### Annual Report and Audited Financial Statements for the year ended 30 June 2023

Independent Auditor's Report to the Members of VPFP International Cautious Fund IC Limited (continued)

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud (continued)

Based on this understanding we designed our audit procedures to identify non-compliance with such laws and
regulations. Our procedures involved the review of minutes of meetings of the Board of Directors; review of
compliance reports; review of correspondence with the Guernsey Financial Services Commission; making inquiries of
those charged with governance; and performance of journal entry testing based on our risk assessment and
understanding of the business, with a focus on non-standard journals and those relating to areas with an identified
associated fraud risk, as described above.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

#### Use of our report

This report is made solely to the Incorporated Cell's members, as a body, in accordance with Section 262 of The Companies (Guernsey) Law 2008 and Paragraph 4.2(4) of the Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021. Our audit work has been undertaken so that we might state to the Incorporated Cell's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Incorporated Cell and the Incorporated Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

4753914588A54C3...

Ernst & Karryll

Ernst & Young LLP Guernsey, Channel Islands

Date: 04 December 2023



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

# Custodian's Report to the Members of VPFP International Cautious Fund IC Limited

In our opinion, the Cell has, in all material aspects, been managed for the year ended 30 June 2023 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021.

For and on behalf of

Northern Trust (Guernsey) Limited

30 November 2023



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

# **Supplementary Information**

	30.06.23	30.06.22
ALLIA ADED OF CHARES OF TEXT AND INC		
NUMBER OF SHARES OUTSTANDING		
Class A	6,548,398	8,373,517
Class B	9,477,332	9,791,211
NET ASSET VALUE PER SHARE - USD		
Class A	1.22	1.16
Class B	1.16	1.10
LUCUECT /LOWECT DDICE LUCD*		
HIGHEST/LOWEST PRICE - USD*	4 22 /4 00	4 20 /4 45
Class A	1.23 / 1.09	1.39 / 1.15
Class B	1.16 / 1.04	1.32 / 1.09
NUMBER OF SHARES SUBSCRIBED		
Class A	351,797	2,282,631
Class B	138,422	465,057
NUMBER OF SHARES REDEEMED		
Class A	2,176,916	6,103,742
Class B	452,301	3,454,743

<sup>\*</sup>The highest/lowest price is based on prices from prior year end to current year end, being 30.06.2023.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

# **Portfolio Statement**

Holdings	Fair Value	% of Net Assets
Holumgs	USD	Assets
Financial assets at fair value through profit or loss	<u> </u>	
Collective Investment Schemes: 91.08% (2022: 85.13%)		
Equity Funds		
iShares Core MSCI EM IMI UCITS ETF 24,651	748,158	3.94
iShares Core MSCI World UCITS ETF 58,038	4,890,282	25.76
Satrix World Equity Tracker Fund – Class L (USD) 827,612	1,071,013	5.64
Total Equity Funds	6,709,453	35.34
Fixed Income Funds	4 0 4 5 0 7 0	
iShares Global Corporate Bond UCITS ETF 363,103	1,846,379	9.73
iShares Global Government Bond UCITS ETF 658,690	2,965,422	15.62
Ninety One Global Strategy Fund - US Dollar Money Fund I Acc USD 60,629	1,330,389	7.01
PIMCO Funds Global Investors Series - Diversified Income Fund Class I 89,900	2,931,637	15.44
PIMCO GIS Global Real Return Fund Institutional USD Accumulation 68,649	1,506,854	7.93
Prescient Global Income Fund Class A 960	1,314	0.01
Total Fixed Income Funds	10,581,995	55.74
Total Collective Investment Schemes	17,291,448	91.08
December 2014 (1997)		
Property and Infrastructure Investment Trusts and ETFs: 4.88% (2022: 5.02%) iShares Global REIT ETF 40.306	025 409	1 00
iShares Global REIT ETF 40,306  Total Property and Infrastructure Investment Trusts and ETFs	925,498 <b>925,498</b>	4.88 <b>4.88</b>
Total Property and Infrastructure investment trusts and ETFS	323,436	4.00
Financial assets at fair value through profit or loss	18,216,946	95.96
Other Net Assets: 4.04% (2022: 9.85%)	766,671	4.04
Net Assets Attributable to Holders of Participating Redeemable Shares	18,983,617	100.00



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

# **Statement of Financial Position**

		Year ended 30.06.23	Year ended 30.06.22
	Notes	<u>USD</u>	USD
ASSETS			
CURRENT ASSETS			
Financial assets at fair value through profit or loss	6	18,216,946	18,477,786
Cash and cash equivalents	7	662,447	2,085,853
Securities sold receivable	3	, -	743,571
Due on issue of redeemable preference shares	3	136,131	-
Deposit interest receivable	3	1,247	-
Other receivables	8	566	645
Total assets	_	19,017,337	21,307,855
LIABILITIES	_		
CURRENT LIABILITIES			
Due on redemption of participating redeemable shares	3	-	775,000
Other payables	9	33,620	36,863
Liabilities (excluding net assets attributable to holders of			
participating redeemable shares)		33,620	811,863
Net assets attributable to holders of participating redeemable shares	3 & 11	18,983,617	20,495,892
Total liabilities		19,017,237	21,307,755
CHAREHOLDERS! FOURTY			
SHAREHOLDERS' EQUITY Management Shares	10	100	100
Total equity		100	100
Total equity	_	100	100
Total equity and liabilities	_	19,017,337	21,307,855
Net asset value per participating redeemable share	11		
Class A		1.22	1.16
Class B		1.16	1.10

The notes 1 to 16 on pages 18 to 32 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 30 November 2023 and signed on its behalf by:

Marie Curutchet

Director

**Robert Rhodes** 

Director



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

# **Statement of Comprehensive Income**

Notes 30.06.23 30.06.2  Notes USD USI  INCOME  Net realised (losses)/gains on financial assets at fair value through profit
INCOME
or loss 6 (216,839) 1,051,89
Change in unrealised gains/(losses) on financial assets at fair value
through profit or loss 6 1,336,293 (4,573,714
Net gains/(losses) on financial assets at fair value through profit or loss 1,119,454 (3,521,823
Deposit interest 16,537 1,98
Dividend income 22,937 22,910
Other foreign exchange gains/(losses) 7 (22
Total net income/(loss) 1,158,935 (3,496,954
OPERATING EXPENSES
Audit fee (7,101) (7,488
Custodian fee (7,101) (7,488
Investment Management fee 13 (179,029) (273,580
Management and Administration fee 13 (57,087) (87,997
Sundry expenses (8,496) (8,608
Total operating expenses (261,314) (393,418
Net profit/(loss) for the year 897,621 (3,890,372
Withholding Tax (6,881) -
Increase/(decrease) in net assets attributable to holders
of participating redeemable shares from operations 890,740 (3,890,372

All items in the above statement derive from continuing operations. There is no difference between the increase/(decrease) in the net assets attributable to holders of participating redeemable shares and comprehensive income.

The notes 1 to 16 on pages 18 to 32 form part of these financial statements.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

### **Statement of Cash Flows**

	Year ended 30.06.23 <u>USD</u>	Year ended 30.06.22 <u>USD</u>
CASH FLOW FROM OPERATING ACTIVITIES		
Increase/(decrease) in net assets attributable to holders of participating		
redeemable shares from operations	890,740	(3,890,372)
ADJUSTMENT FOR:		
Net realised losses/(gains) on financial assets at fair value through profit or loss	216,839	(1,051,891)
Net unrealised (gains)/losses on financial assets at fair value through profit or		
loss	(1,336,293)	4,573,714
Other foreign exchange losses	-	22
Effect of foreign exchange rate on cash	6	-
Dividend income	(22,937)	(22,910)
Withholding tax	6,881	-
Deposit interest	(16,537)	(1,981)
Operating losses before working capital changes	(261,301)	(393,418)
Net decrease/(increase) in other receivables	79	(97)
Net decrease in other payables	(3,243)	(17,935)
Purchase of financial assets at fair value through profit or loss	(4,965,079)	(11,871,935)
Sale of financial assets at fair value through profit or loss	7,088,944	16,998,343
Dividend received	16,056	22,910
Deposit interest received	15,290	1,981
Net cash generated from operating activities	1,890,746	4,739,849
CASH FLOW FROM FINANCING ACTIVITIES		
Cash received from issuance of participating redeemable shares	446,641	3,732,913
Cash paid on redemption of participating redeemable shares	(3,760,787)	(11,672,653)
Net cash used in financing activities	(3,314,146)	(7,939,740)
Net decrease in cash and cash equivalents	(1,423,400)	(3,199,891)
Cash and cash equivalents at the beginning of the year	2,085,853	5,285,766
Effect of foreign exchange rate on cash	(6)	(22)
Cash and cash equivalents at the end of the year	662,447	2,085,853

The notes 1 to 16 on pages 18 to 32 form part of these financial statements.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares

	Note	Year ended 30.06.23 <u>USD</u>	Year ended 30.06.22 <u>USD</u>
Net assets attributable to holders of participating redeemable shares at		20 405 002	22 404 004
the beginning of the year		20,495,892	33,101,004
Proceeds from issuance of participating redeemable shares		582,772	3,732,913
Payments on redemption of participating redeemable shares		(2,985,787)	(12,447,653)
Increase/(decrease) in net assets attributable to holders of participating			
redeemable shares from operations		890,740	(3,890,372)
Net assets attributable to holders of participating redeemable shares at	_		
the end of the year	11 _	18,983,617	20,495,892

The notes 1 to 16 on pages 18 to 32 form part of these financial statements.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 1. General information

The VPFP International Cautious Fund IC Limited (the "Incorporated Cell" or "Cell") with company number 50897, is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company").

The Cell aims to operate a diversified portfolio consisting of assets in liquid form and participatory interests of portfolios of Collective Investment Schemes or other similar schemes, which invest into a wide range of asset classes including cash, fixed income, equities, commodities and property. The portfolio aims to provide a balance between capital preservation and capital growth over the full investment cycle. The Cell is ideally suited to investors with a moderate risk tolerance and with an investment horizon of 3 years or longer.

The Cell intends to achieve its investment objective through a diversified global portfolio as described above. The portfolios have flexibility in terms of currencies and asset allocation both between and within asset classes, countries and regions. The Cell may invest in the units or shares of Collective Investment Schemes which are also managed or operated by the Manager or an associate of the Manager. Neither the Manager nor any such associated company shall be liable to account to investors for any profit, charges or remuneration made or received by the Manager or any such associated company and the Manager's fee shall not be abated thereby.

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager"), with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager"), and Ampersand Asset Management (Pty) Ltd acting as the Sub-Investment Manager.

No amendments were made to the Supplemental Prospectus of the Incorporated Cell during the year.

The financial statements were authorised for issue by the Board of Directors on 30 November 2023.

#### 2. Summary of significant accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements.

# 2.1 Basis of preparation

The financial statements for the Incorporated Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards ("IFRS"). The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss (including derivative financial instruments).

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates, which are disclosed in note 4 of these Incorporated Cell's financial statements. It also requires the Board of Directors to exercise its judgement in the process of applying the Incorporated Cell's accounting policies.

#### **Going concern**

At the time of approving the financial statements, the Board has assessed redemption levels and there have been no significant redemptions. The Board has also considered the liquid nature of the investment portfolio, the absence of any borrowings or commitments and the economic viability of the Cell which is driven by its net asset value.

After careful consideration the Board is satisfied that the Cell has sufficient liquidity to meet its liabilities for the period to 31 December 2024 and therefore it is appropriate to adopt the going concern basis in preparing the financial statements and they have a reasonable expectation that the Cell will continue in existence as a going concern.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 2. Summary of significant accounting policies (continued)

#### 2.2 Adoption of new and revised standards

The Directors have adopted a policy of applying new standards and interpretations when they become effective.

Standards, amendments and interpretations effective during the year

The following accounting standards, amendments and interpretations became effective for the first time in this reporting period:

Periods beginning on or after 1 January 2022:

(a) IFRS 9 - Fees in the '10 per cent ' Test for Derecognition of Financial Liabilities - Amendment to clarify the fees a company includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability.

The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

(b) IFRS 3 - Updating a Reference to the Conceptual Framework - Amendments updated IFRS 3 by replacing a reference to an old version of the Board's Conceptual Framework for Financial Reporting with a reference to the latest version. The adoption of this standard has not had a material impact on the financial statements of the Incorporated Cell.

Standards, amendments and interpretations in issue not yet effective

A number of new Standards, amendments and interpretations are effective for annual periods beginning on or after 1 January 2023 and have not been early adopted in preparing these financial statements. These include:

- (a) IAS 1 Definition of Accounting Estimates (Amendments to IAS 8) Effective from 1 January 2023 Amendments regarding classification of liabilities and disclosure of accounting policies.
- (b) IAS 1 Disclosure Initiative Accounting Policies Effective from 1 January 2023 Amendments to help entities apply materiality judgements to accounting policy disclosure.

The Board anticipates that the adoption of these standards, which will be adopted in the period which they become effective, will not have a material impact on the financial statements of the Cell.

### 2.3 Foreign currency translation

#### (a) Functional and presentation currency

The currency in which the financial information is shown in the financial statements of the Incorporated Cell is deemed to be its functional and presentational currency. In arriving at the functional currency, the Directors have considered the primary economic environment of the Incorporated Cell, and in doing so have considered the currency in which the original capital was raised, any distributions are to be made, performance is evaluated and ultimately, the currency in which capital would be returned on break up basis. They have also considered the currency to which the majority of the underlying investments are exposed and liquidity is managed. The Directors are of the opinion that the currency selected best represent the functional currency.

# (b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 2. Summary of significant accounting policies (continued)

#### 2.4 Financial assets and financial liabilities at fair value through profit or loss

#### (a) Classification

The Incorporated Cell classifies its investments in Collective Investment Schemes, equities and related derivatives as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are classified by the Board of Directors at fair value through profit or loss at inception. The Incorporated Cell does not classify any derivatives as hedges in a hedging relationship. Financial assets and financial liabilities are designated at fair value through profit or loss at inception, are managed, and their performance evaluated on a fair value basis in accordance with the Incorporated Cell's documented investment strategy. The Incorporated Cell's policies are for the Investment Manager and the Board of Directors to evaluate the information about these financial assets on a fair value basis together with other related financial information.

# (b) Recognition/derecognition

Regular-way purchases and sales of investments are recognised on the trade date of the underlying security, so long as the underlying transaction has been confirmed by the relevant counterparty as at the Statement of Financial Position date. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Incorporated Cell has transferred substantially all risks and rewards of ownership.

#### (c) Measurement

Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed in the Statement of Comprehensive Income of the Incorporated Cell. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income in the period in which they arise.

#### (d) Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and trading securities) are based on quoted market prices at the close of trading on the reporting date. The Incorporated Cell adopted to utilise the last traded market price for both financial assets and financial liabilities where the last traded price falls within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the point within the bid-ask spread that is most representative of fair value. As a practical expedient to establish fair value within the bid-ask spread, management will use mid-market pricing. The market price used for assets which are not traded in active markets are those as supplied by their fund administrators.

#### 2.5 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

#### 2.6 Forward currency contracts

Forward foreign currency contracts are treated as derivative contracts and as such are recognised at fair value on the date on which they are entered into and subsequently remeasured at their fair value. Fair value is determined by rates in active currency markets. All derivatives are carried as assets when fair value is positive and as liabilities when fair value is negative. The gain or loss on remeasurement to fair value is recognised immediately through profit or loss in the Statement of Comprehensive Income within other losses and gains in the period in which they arise.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 2. Summary of significant accounting policies (continued)

#### 2.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts.

#### 2.8 Other financial instruments

For other financial instruments, including amounts due to and from brokers and all receivables and payables, the carrying amounts as shown in the Statement of Financial Position approximate to fair value due to the short-term nature of these financial instruments.

#### 2.9 Share capital

The Incorporated Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

#### (a) Management shares

Management shares were issued to comply with Guernsey Company Law, prior to its revision in 2008, under which there had to be a class of non-redeemable shares in issue in order that participating redeemable shares may be issued. The management shares are beneficially owned by the Manager, do not carry any right to dividends, are only entitled to vote at shareholder meetings where there are no participating redeemable shares in issue within the Incorporated Cell and are only entitled to return of capital on the winding up of the Incorporated Cell.

The Incorporated Cell has issued 100 management shares.

#### (b) Participating redeemable shares

The Incorporated Cell's capital is represented by participating redeemable shares with no par value each carrying one vote, no matter which share class. Each share class carries identical rights, the only difference between the classes being either the management fee or the distribution partner fee which is charged to each class. These fees are disclosed in note 13.

The participating redeemable shares are redeemable at the holder's option and are classified as financial liabilities. Participating redeemable shares can be put back to the Incorporated Cell at any time for cash equal to a proportionate share of the Incorporated Cell's net asset value. The participating redeemable share is carried at the redemption amount that is payable at the Statement of Financial Position date if the holder exercises the right to put the share back to the Incorporated Cell.

All participating redeemable shares will rank equally for all dividends and other distributions, as adjusted to reflect any differences in the fees to which each class of participating redeemable share is subject. They are entitled to payment of a proportionate share based on the Cell's net asset value per share on the redemption date. The Cell has no restrictions or specific capital requirements on the subscriptions and redemptions of shares. The relevant movements are shown on the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares. In accordance with the Cell's investment objectives, and its risk management policies, the Cell endeavours to invest the subscriptions received in appropriate investments while maintaining sufficient liquidity to meet redemptions, such liquidity being augmented by short-term borrowings or disposal of listed securities where necessary.

To determine the net asset value of the Cell for subscriptions and redemptions, investments have been valued based on the last traded market prices as of the close of business on the relevant trading day.

#### 2.10 Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations

Income not distributed is included in Net Assets Attributable to Holders of Participating Redeemable Shares of the Incorporated Cell's financial statements.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 2. Summary of significant accounting policies (continued)

#### 2.11 Capital risk management

The fair value of the Cell's financial assets and financial liabilities approximate to its carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Incorporated Cell's objectives when managing capital is to safeguard their ability to continue as a going concern in order to provide returns for shareholders. There are no externally imposed capital requirements on the Incorporated Cell. The Incorporated Cell has no intention to borrow, other than to fund short term liquidity requirements. The Incorporated Cell may arrange an overdraft facility for such purposes.

#### 2.12 Interest and dividend income

Dividend income is recognised when the right to receive payment is established. All deposit interest and other income is accounted for on an accruals basis.

#### 2.13 Expenses

Expenses are accounted for on an accruals basis and all amounts have been allocated to the Statement of Comprehensive Income.

#### 2.14 Custodian bank charges

Custodian bank charges include additional fees on top of the asking price of the security. The bid-asking spread is not disclosed as part of a custodian bank charge. This spread is included in the Statement of Comprehensive Income within the fair value net gain or loss.

#### 2.15 Taxation

The Cell has been granted Exempt Status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,200 (2022: £1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are shown as a separate item in the Statement of Comprehensive Income.

#### 3. Financial risk management

### 3.1 Strategy in using financial instruments

The Cell's activities and investment objectives expose them to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the Cell is exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place throughout the year.

The Cell's policy allows it to use derivative financial instruments to both moderate and create certain risk exposure. The Cell did not hold any derivative financial instrument during the current or prior years.

#### 3.2 Market price risk

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in Collective Investment Schemes. Through its investment in traded securities and instruments the Cell is subject to market movements in the equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions are monitored by the Investment Manager and are reviewed by the Board of Directors.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 3. Financial risk management (continued)

#### 3.2 Market price risk (continued)

The Cell's market price risk is managed through diversification of the investment portfolio by exposure to varying product categories, hence concentration of risk is minimised. At the year end, the financial assets at fair value through profit or loss, which are subject to market price risk, are as follows:

	2023		2022	•
		% of net		% of net
	Fair Value	assets	Fair Value	assets
	<u>USD</u>		<u>USD</u>	
Collective Investment Schemes	17,291,448	91.08	17,448,734	85.13
Property and Infrastructure Investment Trusts and ETFs	925,498	4.88	1,029,052	5.02
·	18,216,946	95.96	18,477,786	90.15

The Cell's market price risk is affected by three main components: changes in actual market prices, interest rate and foreign currency movements. Interest rate and foreign currency exchange rate movements are covered in notes 3.3 and 3.5, respectively. If the market indexes increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2023	2022
	Change in	Change in
	fair value	fair value
	USD	<u>USD</u>
Collective Investment Schemes	1,729,145	1,744,873
Property and Infrastructure Investment Trusts and ETFs	92,550	102,905

#### 3.3 Interest rate risk

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

The table below summarises the Cell's exposure to interest rate risks. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual re-pricing or maturity dates within one month.

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
Net financial assets on which no interest is paid	18,321,170	18,410,039
Net floating rate financial assets	662,447	2,085,853

Should interest rates have increased/decreased by 50 basis points with all other variables remaining constant, the increase/decrease in the net assets attributable to participating redeemable shareholders would amount to approximately:

As at 30 June	2023 <u>USD</u>	2022 <u>USD</u>
Movement in net floating rate financial assets	3,312	10,429



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 3. Financial risk management (continued)

#### 3.4 Cash flow risk

The Cell holds a limited amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.

### 3.5 Currency risk

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets, including investments denominated in currencies other than its functional currency, US Dollar, and therefore it is exposed to currency risk. The exposures are based on the currencies of the underlying assets in the Cell. Investments made via Collective Investment Funds, are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risks:

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
GBP exposure	(9,067)	(10,193)
EUR exposure	158	151
ZAR exposure	(1,966)	-

In accordance with the Cell's policy, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk, however to date the Investment Manager and Board of Directors have deemed that such contracts have not been necessary.

Should the Cell's functional currency have strengthened, or weakened, by 5% against other currencies to which it is exposed, and all other variables, including the price of all investments, had held constant, the net asset attributable to participating redeemable shareholders would have increased, or decreased, as follows:

As at 30 June	2023	2022
	<u>USD</u>	<u>USD</u>
GBP exposure	(453)	(510)
EUR exposure	8	8
ZAR exposure	(98)	-

### 3.6 Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by the Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 3.2. No such redemption problems have been encountered.

All transactions in listed securities are settled/paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period, and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with its cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the Cell. The Northern Trust Company is a wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Cell's maximum exposure to credit risk is the carrying value of the assets on the Statement of Financial Position.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 3. Financial risk management (continued)

# 3.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding their ability to process redemptions as normal.

The Cell has the ability to borrow to meet short term liquidity requirements, however, to date the Cell has not entered into such arrangements.

The table below analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the statement of financial position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.

	Less than 1 month <u>USD</u>	Between 1 and 12 months <u>USD</u>	2023 Total <u>USD</u>	<b>2022</b> Total <u>USD</u>
Financial assets at fair value				
through profit or loss	18,216,946	-	18,216,946	18,477,786
Cash and cash equivalents	662,447	-	662,447	2,085,853
Due on issue of redeemable preference				
shares	136,131	-	136,131	-
Deposit interest receivable	1,247	-	1,247	-
Securities sold receivable	-	-	-	743,571
Other receivables	466	-	466	545
Other payables	(33,620)	-	(33,620)	(36,863)
Due on redemption of participating				
redeemable shares	-	-	-	(775,000)
Net assets attributable to holders of				
participating redeemable shares	(18,983,617)	-	(18,983,617)	(20,495,892)
Net liquidity position	-	-	-	-

Participating redeemable shares are redeemed on demand at the holder's option. However, the Board of Directors does not envisage that the contractual maturity disclosed in the table above will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.

# 3.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The Cell's overall strategy remains unchanged.

The Cell has no externally imposed capital requirements.

### 3.9 Fair value disclosure

In the opinion of the Directors, there are no material differences between the net asset values of the underlying assets and fair values of the financial assets and liabilities.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 4. Critical accounting estimates and judgments

The fair value of investments is considered to be the quoted, active market prices, or prices as supplied by the Fund Administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis. The Cell does not hold any Level 3 investments.

#### 5. Portfolio analysis

The Cell's portfolio is organised by focusing on the type of security held, and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types which are disclosed in note 3.2 and the following main geographical areas:

2023	2022
<u>USD</u>	<u>USD</u>
16,219,121	15,424,883
1,072,327	2,023,851
925,498	1,029,052
18,216,946	18,477,786
	16,219,121 1,072,327 925,498

The geographical segment for listed non-monetary financial assets is considered to be the place of primary listing and for non-listed financial assets where the underlying investment is domiciled.

2022



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 6. Financial assets at fair value through profit or loss

	2023	2022
Financial assets at fair value through profit or loss	<u>USD</u>	<u>USD</u>
Collective Investment Schemes	17,291,448	17,448,734
Property and Infrastructure Investment Trusts and ETFs	925,498	1,029,052
Total financial assets at fair value through profit or loss	18,216,946	18,477,786
Movement on financial assets at fair value through profit or loss		
Fair value of financial assets at the beginning of the year	18,477,786	27,969,425
Purchases of financial assets	4,965,079	10,871,390
Sales of financial assets	(6,345,373)	(16,841,206)
Net realised (losses)/gains on financial assets	(216,839)	1,051,891
Movement in unrealised gains/(losses) on revaluation of financial	1,336,293	(4,573,714)
Fair value of financial assets at the end of the year	18,216,946	18,477,786
Comprising:		
Cost at the end of the year	17,778,771	19,375,904
Unrealised gains/(losses) at the end of the year	438,175	(898,118)
	18,216,946	18,477,786

IFRS 13 requires the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety, is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Cell considers it to be the most advantageous market and would enter into transactions based on those prices.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

# 6. Financial assets at fair value through profit or loss (continued)

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.

The following tables present the Cell's financial assets and financial liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2023 and 30 June 2022:

30 June 2023	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss	USD	USD	USD	USD
Collective Investment Schemes	17,291,448	-	-	17,291,448
Property and Infrastructure Investment Trusts and ETFs	925,498	-	-	925,498
	18,216,946	-	-	18,216,946
30 June 2022	Level 1	Level 2	Level 3	Total
	<u>USD</u>	<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss				
Collective Investment Schemes	17,448,734	-	-	17,448,734
Property and Infrastructure Investment Trusts and ETFs	1,029,052	-	-	1,029,052
	18,477,786	-	-	18,477,786

There were no movements or reclassifications of investments within the levels of the fair value hierarchy during the years ended 30 June 2023 and 30 June 2022.

The Cell's cash and cash equivalents and short-term receivables and payables are recorded at carrying value which approximates fair value.

### 7. Cash and cash equivalents

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	2023	2022
	<u>USD</u>	<u>USD</u>
Cash at bank	662,447	2,085,853
	662,447	2,085,853
8. Other receivables		
	2023	2022
	<u>USD</u>	<u>USD</u>
Prepayments	466	545
Management shares receivable	100	100
	566	645



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

### **Notes to the Financial Statements**

# 9. Other payables

	2023	2022
	<u>USD</u>	<u>USD</u>
Management fee payable	4,619	5,307
Custodian fee payable	1,643	1,676
Investment Management fee payable	14,545	16,400
Audit fee payable	8,725	9,837
Sundry expenses payable	4,088	3,643
	33,620	36,863

# 10. Share capital

The Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

	2023	2022
Management Shares in Issue	USD	<u>USD</u>
Management Shares	100	100
Participating Padagmahla Sharas in Issue Class A	Year ended 30.06.23	Year ended 30.06.22
Participating Redeemable Shares in Issue - Class A  Balance at the beginning of the year	8,373,517	12,194,628
Issue of participating redeemable shares	351,797	2,282,631
	•	
Redemption of participating redeemable shares	(2,176,916)	(6,103,742)
Balance at the end of the year	6,548,398	8,373,517
Participating Redeemable Shares in Issue - Class B		
Balance at the beginning of the year	9,791,211	12,780,897
Issue of participating redeemable shares	138,422	465,057
Redemption of participating redeemable shares	(452,301)	(3,454,743)
Balance at the end of the year	9,477,332	9,791,211

# 11. Net asset value per participating redeemable share

As at 30 June	NAV per share 2023 <u>USD</u>	Net assets attributable 2023 <u>USD</u>	Shares in issue 2023	NAV per share 2022 <u>USD</u>	Net assets attributable 2022 <u>USD</u>	Shares in issue 2022
Class A	1.22	8,012,805	6,548,398	1.16	9,718,482	8,373,517
Class B	1.16	10,970,812	9,477,332	1.10	10,777,410	9,791,211
Total	·	18,983,617	16,025,730	•	20,495,892	18,164,728



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 12. Dividends payable to participating redeemable shareholders

No dividends were paid during the year (2022: Nil) and the Board does not intend to pay any dividends. All available income will be reinvested.

#### 13. Related-party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

### 13.1 Management and Administration fee

The Cell is managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place.

Pursuant to the Management and Administration Agreements, the Manager and the Administrator shall be entitled to receive a fee (the "Management and Administration fee") for the services rendered in connection with the Cell. The Management and Administration fee will accrue as at each Valuation Point, based on the current valuation of the Cell and is payable monthly in arrears, subject to a minimum annual fee of USD22,000 or currency equivalent.

The Management and Administration fee will be chargeable on a sliding scale, in respect of all Share Classes, as follows:

<u>Cell NAV</u>	Fee - % of NAV per annum
Up to USD30m	0.30%
From USD30m to USD60m	0.25%
Over USD60m	0.20%

Management and Administration fee charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	57,087	87,997
Accrued at year end	4,619	5,307

#### 13.2 Investment Management fee

Pursuant to the Investment Management Agreement, Momentum Global Investment Management Limited (the "Investment Manager") is entitled to receive a fee (the "Investment Management fee") of 0.80% of the NAV of the Cell per annum in respect of the Class A shares and 1.05% of the NAV of the Cell per annum in respect of the Class B shares. The Investment Management fee will accrue as at each Valuation Point, based on the current valuation of the Cell and share classes and is payable monthly in arrears.

Investment Management fee charged during the year and accrued at year end:

	2023 <u>USD</u>	2022 <u>USD</u>
Charged during the year 179	9,029	273,580
Accrued at year end 14	4,545	16,400

#### 13.3 Sub-Investment Management fee

The Investment Manager has appointed Ampersand Asset Management (Pty) Ltd, a South African registered company as Sub-Investment Manager to the Cell (the "Sub-Investment Manager"). The Sub-Investment Manager is entitled to receive a fee (the "Sub-Investment Management fee") of 0.75% of the NAV of the Cell per annum in respect of the Class A shares and 1.00% of the NAV of the Cell per annum in respect of the Class B shares which will be paid out of the fee received by the Investment Manager. The Sub-Investment Management fee will accrue as at each Valuation Point, based on the current valuation of the Cell and is payable monthly in arrears.



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

#### **Notes to the Financial Statements**

#### 13. Related-party transactions (continued)

#### 13.4 Custodian fee

The Cell has engaged the services of Northern Trust (Guernsey) Limited to provide custodian services. The Custodian is entitled to the payment of a fee (the "Custody fee") chargeable on a sliding scale in respect of all Share Classes, as follows, subject to a minimum of USD8,000 per annum.

Fee - % of NAV per annum	<u>Cell NAV</u>
0.05%	Up to USD30m
0.04%	From USD30m to USD60m
0.03%	From USD60m to USD100m
0.02%	Over USD100m

Custodian fee charged during the year and accrued at year end:

	2023	2022
	<u>USD</u>	<u>USD</u>
Charged during the year	9,601	15,745
Accrued at year end	1,643	1,676

#### 13.5 Distribution Partner fee

The Cell has appointed Vickers & Peters Financial Planning (Pty) Limited as distribution partner to promote and market the Cell. The Distribution Partner will not be paid a fee.

#### 13.6 Board of Directors' remuneration

Directors' fees in respect of the Cell shall not exceed USD20,000 or currency equivalent in any twelve-month period. In addition, the Directors shall be entitled to be repaid for all reasonable out of pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of the Cell alone and not from the cellular assets of other Cell of the Company or assets of the Company itself.

The Directors waived their right to a fee in 2023 (2022: Nil).

# 14. Ultimate controlling party

In the opinion of the Directors, on the basis of the shareholdings advised to them, the Cell has no ultimate controlling party.

### 15. Reconciliation of published valuation to financial statements

	<u>USD</u>	<u>USD</u>
Net assets attributable to holders of participating redeemable shares		
per financial statements	18,983,617	20,495,892
Adjustments:		
Adjustment in value of financial assets at fair value through profit or loss	(11,587)	23,591
Adjustment to accrue for rebranding of financial statements		441
Net assets attributable to holders of participating redeemable shares		
per published valuation	18,972,030	20,519,924
NAV per Class A share per published valuation	1.22	1.16
NAV per Class B share per published valuation	1.16	1.10
NAV per Class A share per financial statements	1.22	1.16
NAV per Class B share per financial statements	1.16	1.10

2022

2023



# Annual Report and Audited Financial Statements for the year ended 30 June 2023

### **Notes to the Financial Statements**

#### 16. Subsequent events

These financial statements were approved for issuance by the Board on 30 November 2023. Subsequent events have been evaluated until this date.

On 7 August 2023, the following amendments were made to the Supplemental Prospectus of the Cell and were effective from that date:

- The Management Agreement has been adjusted to reflect that the Manager shall settle the fees of the Administrator and the Investment Manager on behalf of the Cell from the proceeds of the Management Fee. The Manager shall be entitled to the payment of a fee of 0.3% of the NAV of the Cell per annum (subject to a minimum fee of USD40,000 per annum);
- Due to the above changes the Sub- Investment Management Fee will no longer be paid out of the fee received by the Investment Manager;
- The Directors' fees have been adjusted to USD10,000 per annum; and
- The Commission has agreed to disapply rule 2.07(10) of the Rules to the Cell (previously 2.08(9) of the Rules), as detailed in Prospectus.

No further significant subsequent events have occurred in respect of the Cell that are considered material to the understanding of these audited financial statements.